OREXO AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2 USD | +16.28% |
|
-9.50% | +32.45% |
| 05-08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +32.45% | 69.75M | - | ||
| +17.03% | 9.11B | A- | ||
| -23.31% | 4.44B | A- | ||
| +15.70% | 4.24B | B- | ||
| +32.83% | 4.03B | - | ||
| +9.37% | 2.14B | B | ||
| +9.30% | 1.94B | - | - | |
| -33.37% | 1.9B | C- | ||
| -0.50% | 1.64B | - | - | |
| -46.20% | 1.63B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Ratings Orexo AB
